FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Virol / Equine infectious anemia virus and the ubiquitin-proteasome ...
Journal of virology2002; 76(6); 3038-3044; doi: 10.1128/jvi.76.6.3038-3044.2002

Equine infectious anemia virus and the ubiquitin-proteasome system.

Abstract: Some retroviruses contain monoubiquitinated Gag and do not bud efficiently from cells treated with proteasome inhibitors, suggesting an interaction between the ubiquitin-proteasome system and retrovirus assembly. We examined equine infectious anemia virus (EIAV) particles and found that approximately 2% of the p9(Gag) proteins are monoubiquitinated, demonstrating that this Gag protein interacts with an ubiquitinating activity. Different types of proteasome inhibitors were used to determine if proteasome inactivation affects EIAV release from chronically infected cells. Pulse-chase immunoprecipitation and time course immunoblot analyses showed that proteasome inactivation slightly decreased virus release (at most a twofold effect), while it did not affect Gag processing. These results contrast with those obtained with other viruses which are sensitive to these inhibitors. This suggests that, although its Gag is monoubiquitinated, the requirements for EIAV release are somewhat different from those for retroviruses that are sensitive to proteasome inhibitors.
Get Full Text
Publication Date: 2002-02-28 PubMed ID: 11861870PubMed Central: PMC135975DOI: 10.1128/jvi.76.6.3038-3044.2002Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article investigates the relationship between the equine infectious anemia virus (EIAV) and the ubiquitin-proteasome system, a critical part of cellular function and virus assembly. The study found that EIAV reacts differently than other viruses to proteasome inhibitors, indicating distinctive mechanisms in the EIAV release process.

Interaction of EIAV Gag Proteins and Ubiquitin

  • The researchers first looked at the EIAV particles and found that approximately 2% of the p9(Gag) proteins in them are monoubiquitinated. This indicates that this particular protein interacts with ubiquitinating activity.
  • Ubiquitination is a process that tags proteins for degradation or to alter their cellular functions. In this case, the p9(Gag) proteins being monoubiquitinated suggests that there is an interaction between the virus and the ubiquitin-proteasome system, which is involved in the degradation of unnecessary or damaged proteins in the cell.

Impact of Proteasome Inhibition on EIAV

  • Different types of proteasome inhibitors were used to evaluate if there is a relationship between proteasome activity and the release of the EIAV from cells.
  • Proteasome inhibitors are compounds that disrupt the proteasome’s function, potentially impacting the virus’s life cycle. These compounds were used based on previously observed behavior in other retroviruses that did not bud efficiently when cells were treated with proteasomes inhibitors.
  • After applying proteasome inhibitors, the study found that virus release slightly decreased while the processing of Gag proteins remained unaffected. The decrease in virus release was minimal, showing at most a twofold effect.

Comparison with Other Retroviruses

  • The results obtained from this study contrasted with those obtained with other viruses which were more sensitive to proteasome inhibitors.
  • Despite the Gag protein of EIAV being monoubiquitinated (similar to some other retroviruses), the release process of EIAV behaved differently under proteasome inhibition. This suggests that the requirements for the release of EIAV are not exactly the same as for other retroviruses that are more sensitive to the effects of proteasome inhibitors.

Cite This Article

APA
Ott DE, Coren LV, Sowder RC, Adams J, Nagashima K, Schubert U. (2002). Equine infectious anemia virus and the ubiquitin-proteasome system. J Virol, 76(6), 3038-3044. https://doi.org/10.1128/jvi.76.6.3038-3044.2002

Publication

Journal of virology
ISSN: 0022-538X
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 76
Issue: 6
Pages: 3038-3044

Researcher Affiliations

Ott, David E
  • AIDS Vaccine Program, SAIC Frederick, National Cancer Institute at Frederick, National Institutes of Health, Frederick, Maryland 21702, USA. ott@ncifcrf.gov
Coren, Lori V
    Sowder, Raymond C
      Adams, Julian
        Nagashima, Kunio
          Schubert, Ulrich

            MeSH Terms

            • Animals
            • Cell Line
            • Cysteine Endopeptidases / metabolism
            • Enzyme Inhibitors / pharmacology
            • Equine Infectious Anemia / virology
            • Gene Products, gag / metabolism
            • Infectious Anemia Virus, Equine / drug effects
            • Infectious Anemia Virus, Equine / physiology
            • Multienzyme Complexes / antagonists & inhibitors
            • Multienzyme Complexes / metabolism
            • Proteasome Endopeptidase Complex
            • Ubiquitin / metabolism
            • Virus Assembly

            Grant Funding

            • N01-CO-56000 / NCI NIH HHS

            References

            This article includes 55 references
            1. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.. Bioorg Med Chem Lett 1998 Feb 17;8(4):333-8.
              pubmed: 9871680doi: 10.1016/s0960-894x(98)00029-8google scholar: lookup
            2. Bess JW Jr, Gorelick RJ, Bosche WJ, Henderson LE, Arthur LO. Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.. Virology 1997 Mar 31;230(1):134-44.
              pubmed: 9126269doi: 10.1006/viro.1997.8499google scholar: lookup
            3. Ciechanover A. The ubiquitin-proteasome proteolytic pathway.. Cell 1994 Oct 7;79(1):13-21.
              pubmed: 7923371doi: 10.1016/0092-8674(94)90396-4google scholar: lookup
            4. Craiu A, Gaczynska M, Akopian T, Gramm CF, Fenteany G, Goldberg AL, Rock KL. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation.. J Biol Chem 1997 May 16;272(20):13437-45.
              pubmed: 9148969doi: 10.1074/jbc.272.20.13437google scholar: lookup
            5. D'Andrea A, Pellman D. Deubiquitinating enzymes: a new class of biological regulators.. Crit Rev Biochem Mol Biol 1998;33(5):337-52.
              pubmed: 9827704doi: 10.1080/10409239891204251google scholar: lookup
            6. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin.. Science 1995 May 5;268(5211):726-31.
              pubmed: 7732382doi: 10.1126/science.7732382google scholar: lookup
            7. Finley D, Chau V. Ubiquitination.. Annu Rev Cell Biol 1991;7:25-69.
              pubmed: 1667082doi: 10.1146/annurev.cb.07.110191.000325google scholar: lookup
            8. Garnier L, Wills JW, Verderame MF, Sudol M. WW domains and retrovirus budding.. Nature 1996 Jun 27;381(6585):744-5.
              pubmed: 8657277doi: 10.1038/381744a0google scholar: lookup
            9. Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Côté M, Rich RL, Myszka DG, Sundquist WI. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding.. Cell 2001 Oct 5;107(1):55-65.
              pubmed: 11595185doi: 10.1016/s0092-8674(01)00506-2google scholar: lookup
            10. Gluschankof P, Mondor I, Gelderblom HR, Sattentau QJ. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations.. Virology 1997 Mar 31;230(1):125-33.
              pubmed: 9126268doi: 10.1006/viro.1997.8453google scholar: lookup
            11. Göttlinger HG, Dorfman T, Sodroski JG, Haseltine WA. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.. Proc Natl Acad Sci U S A 1991 Apr 15;88(8):3195-9.
              pmc: PMC51412pubmed: 2014240doi: 10.1073/pnas.88.8.3195google scholar: lookup
            12. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding.. Proc Natl Acad Sci U S A 2000 Dec 5;97(25):13871-6.
              pmc: PMC17668pubmed: 11095724doi: 10.1073/pnas.250277297google scholar: lookup
            13. Harty RN, Paragas J, Sudol M, Palese P. A proline-rich motif within the matrix protein of vesicular stomatitis virus and rabies virus interacts with WW domains of cellular proteins: implications for viral budding.. J Virol 1999 Apr;73(4):2921-9.
              pmc: PMC104051pubmed: 10074141doi: 10.1128/jvi.73.4.2921-2929.1999google scholar: lookup
            14. Henderson LE, Bowers MA, Sowder RC 2nd, Serabyn SA, Johnson DG, Bess JW Jr, Arthur LO, Bryant DK, Fenselau C. Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.. J Virol 1992 Apr;66(4):1856-65.
              pmc: PMC288972pubmed: 1548743doi: 10.1128/jvi.66.4.1856-1865.1992google scholar: lookup
            15. Hershko A, Ciechanover A. The ubiquitin system.. Annu Rev Biochem 1998;67:425-79.
              pubmed: 9759494doi: 10.1146/annurev.biochem.67.1.425google scholar: lookup
            16. Hicke L. Protein regulation by monoubiquitin.. Nat Rev Mol Cell Biol 2001 Mar;2(3):195-201.
              pubmed: 11265249doi: 10.1038/35056583google scholar: lookup
            17. Hochstrasser M. Ubiquitin-dependent protein degradation.. Annu Rev Genet 1996;30:405-39.
              pubmed: 8982460doi: 10.1146/annurev.genet.30.1.405google scholar: lookup
            18. Huang M, Orenstein JM, Martin MA, Freed EO. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.. J Virol 1995 Nov;69(11):6810-8.
              pmc: PMC189593pubmed: 7474093doi: 10.1128/jvi.69.11.6810-6818.1995google scholar: lookup
            19. Kikonyogo A, Bouamr F, Vana ML, Xiang Y, Aiyar A, Carter C, Leis J. Proteins related to the Nedd4 family of ubiquitin protein ligases interact with the L domain of Rous sarcoma virus and are required for gag budding from cells.. Proc Natl Acad Sci U S A 2001 Sep 25;98(20):11199-204.
              pmc: PMC58707pubmed: 11562473doi: 10.1073/pnas.201268998google scholar: lookup
            20. Kloetzel PM. Antigen processing by the proteasome.. Nat Rev Mol Cell Biol 2001 Mar;2(3):179-87.
              pubmed: 11265247doi: 10.1038/35056572google scholar: lookup
            21. Laney JD, Hochstrasser M. Substrate targeting in the ubiquitin system.. Cell 1999 May 14;97(4):427-30.
              pubmed: 10338206doi: 10.1016/s0092-8674(00)80752-7google scholar: lookup
            22. Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, Moore JP, Raina JL, Renz H, Gelderblom HR, Nara PL. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.. Virology 1992 Aug;189(2):695-714.
              pubmed: 1386485doi: 10.1016/0042-6822(92)90593-egoogle scholar: lookup
            23. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists.. Trends Cell Biol 1998 Oct;8(10):397-403.
              pubmed: 9789328doi: 10.1016/s0962-8924(98)01346-4google scholar: lookup
            24. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. Protein measurement with the Folin phenol reagent.. J Biol Chem 1951 Nov;193(1):265-75.
              pubmed: 14907713
            25. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.. Proc Natl Acad Sci U S A 1999 Aug 31;96(18):10403-8.
              pmc: PMC17900pubmed: 10468620doi: 10.1073/pnas.96.18.10403google scholar: lookup
            26. Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U. Ubiquitination of HIV-1 and MuLV Gag.. Virology 2000 Dec 5;278(1):111-21.
              pubmed: 11112487doi: 10.1006/viro.2000.0648google scholar: lookup
            27. Ott DE, Coren LV, Copeland TD, Kane BP, Johnson DG, Sowder RC 2nd, Yoshinaka Y, Oroszlan S, Arthur LO, Henderson LE. Ubiquitin is covalently attached to the p6Gag proteins of human immunodeficiency virus type 1 and simian immunodeficiency virus and to the p12Gag protein of Moloney murine leukemia virus.. J Virol 1998 Apr;72(4):2962-8.
              pmc: PMC109742pubmed: 9525617doi: 10.1128/jvi.72.4.2962-2968.1998google scholar: lookup
            28. Ott DE, Coren LV, Johnson DG, Kane BP, Sowder RC 2nd, Kim YD, Fisher RJ, Zhou XZ, Lu KP, Henderson LE. Actin-binding cellular proteins inside human immunodeficiency virus type 1.. Virology 2000 Jan 5;266(1):42-51.
              pubmed: 10612659doi: 10.1006/viro.1999.0075google scholar: lookup
            29. Ott DE, Coren LV, Johnson DG, Sowder RC 2nd, Arthur LO, Henderson LE. Analysis and localization of cyclophilin A found in the virions of human immunodeficiency virus type 1 MN strain.. AIDS Res Hum Retroviruses 1995 Sep;11(9):1003-6.
              pubmed: 8554896doi: 10.1089/aid.1995.11.1003google scholar: lookup
            30. Ott DE, Coren LV, Kane BP, Busch LK, Johnson DG, Sowder RC 2nd, Chertova EN, Arthur LO, Henderson LE. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions.. J Virol 1996 Nov;70(11):7734-43.
              pmc: PMC190843pubmed: 8892894doi: 10.1128/jvi.70.11.7734-7743.1996google scholar: lookup
            31. Patnaik A, Chau V, Wills JW. Ubiquitin is part of the retrovirus budding machinery.. Proc Natl Acad Sci U S A 2000 Nov 21;97(24):13069-74.
              pmc: PMC27179pubmed: 11087861doi: 10.1073/pnas.97.24.13069google scholar: lookup
            32. Patnaik A, Chau V, Li F, Montelaro RC, Wills JW. Budding of equine infectious anemia virus is insensitive to proteasome inhibitors.. J Virol 2002 Mar;76(6):2641-7.
              pmc: PMC135976pubmed: 11861830doi: 10.1128/jvi.76.6.2641-2647.2002google scholar: lookup
            33. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.. Science 1993 Mar 19;259(5102):1749-54.
              pubmed: 8096089doi: 10.1126/science.8096089google scholar: lookup
            34. Princiotta MF, Schubert U, Chen W, Bennink JR, Myung J, Crews CM, Yewdell JW. Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival.. Proc Natl Acad Sci U S A 2001 Jan 16;98(2):513-8.
              pmc: PMC14618pubmed: 11149939doi: 10.1073/pnas.98.2.513google scholar: lookup
            35. Puffer BA, Parent LJ, Wills JW, Montelaro RC. Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein.. J Virol 1997 Sep;71(9):6541-6.
              pmc: PMC191930pubmed: 9261374doi: 10.1128/jvi.71.9.6541-6546.1997google scholar: lookup
            36. Puffer BA, Watkins SC, Montelaro RC. Equine infectious anemia virus Gag polyprotein late domain specifically recruits cellular AP-2 adapter protein complexes during virion assembly.. J Virol 1998 Dec;72(12):10218-21.
              pmc: PMC110572pubmed: 9811764doi: 10.1128/jvi.72.12.10218-10221.1998google scholar: lookup
            37. Putterman D, Pepinsky RB, Vogt VM. Ubiquitin in avian leukosis virus particles.. Virology 1990 Jun;176(2):633-7.
              pubmed: 2161153doi: 10.1016/0042-6822(90)90035-pgoogle scholar: lookup
            38. Schubert U, Antón LC, Bacík I, Cox JH, Bour S, Bennink JR, Orlowski M, Strebel K, Yewdell JW. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.. J Virol 1998 Mar;72(3):2280-8.
              pmc: PMC109526pubmed: 9499087doi: 10.1128/jvi.72.3.2280-2288.1998google scholar: lookup
            39. Schubert U, Antón LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.. Nature 2000 Apr 13;404(6779):770-4.
              pubmed: 10783891doi: 10.1038/35008096google scholar: lookup
            40. Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Krausslich HG, Yewdell JW. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.. Proc Natl Acad Sci U S A 2000 Nov 21;97(24):13057-62.
              pmc: PMC27177pubmed: 11087859doi: 10.1073/pnas.97.24.13057google scholar: lookup
            41. Strack B, Calistri A, Accola MA, Palu G, Gottlinger HG. A role for ubiquitin ligase recruitment in retrovirus release.. Proc Natl Acad Sci U S A 2000 Nov 21;97(24):13063-8.
              pmc: PMC27178pubmed: 11087860doi: 10.1073/pnas.97.24.13063google scholar: lookup
            42. Summers MF, Henderson LE, Chance MR, Bess JW Jr, South TL, Blake PR, Sagi I, Perez-Alvarado G, Sowder RC 3rd, Hare DR. Nucleocapsid zinc fingers detected in retroviruses: EXAFS studies of intact viruses and the solution-state structure of the nucleocapsid protein from HIV-1.. Protein Sci 1992 May;1(5):563-74.
              pmc: PMC2142235pubmed: 1304355doi: 10.1002/pro.5560010502google scholar: lookup
            43. Swanstrom R, Wills J. Synthesis, assembly, and processing of viral proteins. Retroviruses p. 263-334.
            44. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal.. EMBO J 2000 Jan 4;19(1):94-102.
              pmc: PMC1171781pubmed: 10619848doi: 10.1093/emboj/19.1.94google scholar: lookup
            45. Tsubuki S, Saito Y, Tomioka M, Ito H, Kawashima S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine.. J Biochem 1996 Mar;119(3):572-6.
              pubmed: 8830056doi: 10.1093/oxfordjournals.jbchem.a021280google scholar: lookup
            46. VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J, Carter CA. Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag).. Proc Natl Acad Sci U S A 2001 Jul 3;98(14):7724-9.
              pmc: PMC35409pubmed: 11427703doi: 10.1073/pnas.131059198google scholar: lookup
            47. Vogt V. Retroviral virions and genomes. Retroviruses p. 27-70.
            48. Vogt VM. Ubiquitin in retrovirus assembly: actor or bystander?. Proc Natl Acad Sci U S A 2000 Nov 21;97(24):12945-7.
              pmc: PMC34070pubmed: 11087848doi: 10.1073/pnas.97.24.12945google scholar: lookup
            49. Vogt VM, Simon MN. Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy.. J Virol 1999 Aug;73(8):7050-5.
              pmc: PMC112795pubmed: 10400808doi: 10.1128/jvi.73.8.7050-7055.1999google scholar: lookup
            50. Weissman AM. Themes and variations on ubiquitylation.. Nat Rev Mol Cell Biol 2001 Mar;2(3):169-78.
              pubmed: 11265246doi: 10.1038/35056563google scholar: lookup
            51. Wilkinson KD. Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome.. Semin Cell Dev Biol 2000 Jun;11(3):141-8.
              pubmed: 10906270doi: 10.1006/scdb.2000.0164google scholar: lookup
            52. Wills JW, Cameron CE, Wilson CB, Xiang Y, Bennett RP, Leis J. An assembly domain of the Rous sarcoma virus Gag protein required late in budding.. J Virol 1994 Oct;68(10):6605-18.
              pmc: PMC237081pubmed: 8083996doi: 10.1128/jvi.68.10.6605-6618.1994google scholar: lookup
            53. Xiang Y, Cameron CE, Wills JW, Leis J. Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain.. J Virol 1996 Aug;70(8):5695-700.
              pmc: PMC190537pubmed: 8764091doi: 10.1128/jvi.70.8.5695-5700.1996google scholar: lookup
            54. Yasuda J, Hunter E. A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release.. J Virol 1998 May;72(5):4095-103.
              pmc: PMC109639pubmed: 9557699doi: 10.1128/jvi.72.5.4095-4103.1998google scholar: lookup
            55. Yuan B, Campbell S, Bacharach E, Rein A, Goff SP. Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses.. J Virol 2000 Aug;74(16):7250-60.
              pmc: PMC112246pubmed: 10906179doi: 10.1128/jvi.74.16.7250-7260.2000google scholar: lookup

            Citations

            This article has been cited 41 times.
            1. Bussienne C, Marquet R, Paillart JC, Bernacchi S. Post-Translational Modifications of Retroviral HIV-1 Gag Precursors: An Overview of Their Biological Role.. Int J Mol Sci 2021 Mar 11;22(6).
              doi: 10.3390/ijms22062871pubmed: 33799890google scholar: lookup
            2. Coren LV, Nagashima K, Ott DE. A PLPPV sequence in the p8 region of Gag provides late domain function for mouse mammary tumor virus.. Virology 2019 Sep;535:272-278.
              doi: 10.1016/j.virol.2019.07.015pubmed: 31357166google scholar: lookup
            3. Huang X, Wei S, Ni S, Huang Y, Qin Q. Ubiquitin-Proteasome System Is Required for Efficient Replication of Singapore Grouper Iridovirus.. Front Microbiol 2018;9:2798.
              doi: 10.3389/fmicb.2018.02798pubmed: 30534113google scholar: lookup
            4. Su Y, Shi P, Zhang L, Lu D, Zhao C, Li R, Zhang L, Huang J. The Superimposed Deubiquitination Effect of OTULIN and Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) Nsp11 Promotes Multiplication of PRRSV.. J Virol 2018 May 1;92(9).
              doi: 10.1128/JVI.00175-18pubmed: 29444948google scholar: lookup
            5. Sabino Cunha M, Lima Sampaio T, Peterlin BM, Jesus da Costa L. A Truncated Nef Peptide from SIVcpz Inhibits the Production of HIV-1 Infectious Progeny.. Viruses 2016 Jul 7;8(7).
              doi: 10.3390/v8070189pubmed: 27399760google scholar: lookup
            6. Zhang Z, Ma J, Zhang X, Su C, Yao QC, Wang X. Equine Infectious Anemia Virus Gag Assembly and Export Are Directed by Matrix Protein through trans-Golgi Networks and Cellular Vesicles.. J Virol 2016 Feb 15;90(4):1824-38.
              doi: 10.1128/JVI.02814-15pubmed: 26637458google scholar: lookup
            7. Coren LV, Trivett MT, Jain S, Ayala VI, Del Prete GQ, Ohlen C, Ott DE. Potent restriction of HIV-1 and SIVmac239 replication by African green monkey TRIM5α.. Retrovirology 2015 Feb 7;12:11.
              doi: 10.1186/s12977-015-0137-9pubmed: 25809491google scholar: lookup
            8. Hütter S, Zurnic I, Lindemann D. Foamy virus budding and release.. Viruses 2013 Apr 10;5(4):1075-98.
              doi: 10.3390/v5041075pubmed: 23575110google scholar: lookup
            9. Greene W, Zhang W, He M, Witt C, Ye F, Gao SJ. The ubiquitin/proteasome system mediates entry and endosomal trafficking of Kaposi's sarcoma-associated herpesvirus in endothelial cells.. PLoS Pathog 2012;8(5):e1002703.
              doi: 10.1371/journal.ppat.1002703pubmed: 22615563google scholar: lookup
            10. Dorjbal B, Derse D, Lloyd P, Soheilian F, Nagashima K, Heidecker G. The role of ITCH protein in human T-cell leukemia virus type 1 release.. J Biol Chem 2011 Sep 9;286(36):31092-104.
              doi: 10.1074/jbc.M111.259945pubmed: 21724848google scholar: lookup
            11. Liu Y, Cocka L, Okumura A, Zhang YA, Sunyer JO, Harty RN. Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles.. J Virol 2010 Mar;84(5):2294-303.
              doi: 10.1128/JVI.02034-09pubmed: 20032189google scholar: lookup
            12. Sharma A, Bruns K, Röder R, Henklein P, Votteler J, Wray V, Schubert U. Solution structure of the equine infectious anemia virus p9 protein: a rationalization of its different ALIX binding requirements compared to the analogous HIV-p6 protein.. BMC Struct Biol 2009 Dec 17;9:74.
              doi: 10.1186/1472-6807-9-74pubmed: 20015412google scholar: lookup
            13. Joshi A, Nagashima K, Freed EO. Defects in cellular sorting and retroviral assembly induced by GGA overexpression.. BMC Cell Biol 2009 Sep 29;10:72.
              doi: 10.1186/1471-2121-10-72pubmed: 19788741google scholar: lookup
            14. Harty RN, Pitha PM, Okumura A. Antiviral activity of innate immune protein ISG15.. J Innate Immun 2009;1(5):397-404.
              doi: 10.1159/000226245pubmed: 19680460google scholar: lookup
            15. Patch JR, Han Z, McCarthy SE, Yan L, Wang LF, Harty RN, Broder CC. The YPLGVG sequence of the Nipah virus matrix protein is required for budding.. Virol J 2008 Nov 10;5:137.
              doi: 10.1186/1743-422X-5-137pubmed: 19000317google scholar: lookup
            16. Joshi A, Munshi U, Ablan SD, Nagashima K, Freed EO. Functional replacement of a retroviral late domain by ubiquitin fusion.. Traffic 2008 Nov;9(11):1972-83.
              doi: 10.1111/j.1600-0854.2008.00817.xpubmed: 18817521google scholar: lookup
            17. Okumura A, Pitha PM, Harty RN. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity.. Proc Natl Acad Sci U S A 2008 Mar 11;105(10):3974-9.
              doi: 10.1073/pnas.0710629105pubmed: 18305167google scholar: lookup
            18. Zhadina M, McClure MO, Johnson MC, Bieniasz PD. Ubiquitin-dependent virus particle budding without viral protein ubiquitination.. Proc Natl Acad Sci U S A 2007 Dec 11;104(50):20031-6.
              doi: 10.1073/pnas.0708002104pubmed: 18056634google scholar: lookup
            19. Calistri A, Sette P, Salata C, Cancellotti E, Forghieri C, Comin A, Göttlinger H, Campadelli-Fiume G, Palù G, Parolin C. Intracellular trafficking and maturation of herpes simplex virus type 1 gB and virus egress require functional biogenesis of multivesicular bodies.. J Virol 2007 Oct;81(20):11468-78.
              doi: 10.1128/JVI.01364-07pubmed: 17686835google scholar: lookup
            20. Heidecker G, Lloyd PA, Soheilian F, Nagashima K, Derse D. The role of WWP1-Gag interaction and Gag ubiquitination in assembly and release of human T-cell leukemia virus type 1.. J Virol 2007 Sep;81(18):9769-77.
              doi: 10.1128/JVI.00642-07pubmed: 17609263google scholar: lookup
            21. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release.. J Virol 2006 Mar;80(6):2924-32.
              doi: 10.1128/JVI.80.6.2924-2932.2006pubmed: 16501101google scholar: lookup
            22. Hui EK, Barman S, Tang DH, France B, Nayak DP. YRKL sequence of influenza virus M1 functions as the L domain motif and interacts with VPS28 and Cdc42.. J Virol 2006 Mar;80(5):2291-308.
              doi: 10.1128/JVI.80.5.2291-2308.2006pubmed: 16474136google scholar: lookup
            23. Stanke N, Stange A, Lüftenegger D, Zentgraf H, Lindemann D. Ubiquitination of the prototype foamy virus envelope glycoprotein leader peptide regulates subviral particle release.. J Virol 2005 Dec;79(24):15074-83.
              doi: 10.1128/JVI.79.24.15074-15083.2005pubmed: 16306578google scholar: lookup
            24. Ott DE, Coren LV, Gagliardi TD, Nagashima K. Heterologous late-domain sequences have various abilities to promote budding of human immunodeficiency virus type 1.. J Virol 2005 Jul;79(14):9038-45.
              doi: 10.1128/jvi.79.14.9038-9045.2005pubmed: 15994797google scholar: lookup
            25. Irie T, Licata JM, Harty RN. Functional characterization of Ebola virus L-domains using VSV recombinants.. Virology 2005 Jun 5;336(2):291-8.
              doi: 10.1016/j.virol.2005.03.027pubmed: 15892969google scholar: lookup
            26. Johnson MC, Spidel JL, Ako-Adjei D, Wills JW, Vogt VM. The C-terminal half of TSG101 blocks Rous sarcoma virus budding and sequesters Gag into unique nonendosomal structures.. J Virol 2005 Mar;79(6):3775-86.
              doi: 10.1128/JVI.79.6.3775-3786.2005pubmed: 15731271google scholar: lookup
            27. Schmitt AP, Leser GP, Morita E, Sundquist WI, Lamb RA. Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus.. J Virol 2005 Mar;79(5):2988-97.
              doi: 10.1128/JVI.79.5.2988-2997.2005pubmed: 15709019google scholar: lookup
            28. Martin-Serrano J, Eastman SW, Chung W, Bieniasz PD. HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway.. J Cell Biol 2005 Jan 3;168(1):89-101.
              doi: 10.1083/jcb.200408155pubmed: 15623582google scholar: lookup
            29. Spidel JL, Craven RC, Wilson CB, Patnaik A, Wang H, Mansky LM, Wills JW. Lysines close to the Rous sarcoma virus late domain critical for budding.. J Virol 2004 Oct;78(19):10606-16.
              doi: 10.1128/JVI.78.19.10606-10616.2004pubmed: 15367628google scholar: lookup
            30. Martin-Serrano J, Perez-Caballero D, Bieniasz PD. Context-dependent effects of L domains and ubiquitination on viral budding.. J Virol 2004 Jun;78(11):5554-63.
              doi: 10.1128/JVI.78.11.5554-5563.2004pubmed: 15140952google scholar: lookup
            31. Irie T, Licata JM, McGettigan JP, Schnell MJ, Harty RN. Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A.. J Virol 2004 Mar;78(6):2657-65.
              doi: 10.1128/jvi.78.6.2657-2665.2004pubmed: 14990685google scholar: lookup
            32. Yung E, Sorin M, Wang EJ, Perumal S, Ott D, Kalpana GV. Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance.. J Virol 2004 Mar;78(5):2222-31.
              doi: 10.1128/jvi.78.5.2222-2231.2004pubmed: 14963118google scholar: lookup
            33. Shehu-Xhilaga M, Ablan S, Demirov DG, Chen C, Montelaro RC, Freed EO. Late domain-dependent inhibition of equine infectious anemia virus budding.. J Virol 2004 Jan;78(2):724-32.
              doi: 10.1128/jvi.78.2.724-732.2004pubmed: 14694104google scholar: lookup
            34. Bouamr F, Melillo JA, Wang MQ, Nagashima K, de Los Santos M, Rein A, Goff SP. PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected].. J Virol 2003 Nov;77(22):11882-95.
              doi: 10.1128/jvi.77.22.11882-11895.2003pubmed: 14581525google scholar: lookup
            35. Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz PD. Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins.. Proc Natl Acad Sci U S A 2003 Oct 14;100(21):12414-9.
              doi: 10.1073/pnas.2133846100pubmed: 14519844google scholar: lookup
            36. Tanzi GO, Piefer AJ, Bates P. Equine infectious anemia virus utilizes host vesicular protein sorting machinery during particle release.. J Virol 2003 Aug;77(15):8440-7.
              doi: 10.1128/jvi.77.15.8440-8447.2003pubmed: 12857913google scholar: lookup
            37. Goila-Gaur R, Demirov DG, Orenstein JM, Ono A, Freed EO. Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression.. J Virol 2003 Jun;77(11):6507-19.
              doi: 10.1128/jvi.77.11.6507-6519.2003pubmed: 12743307google scholar: lookup
            38. Martin-Serrano J, Zang T, Bieniasz PD. Role of ESCRT-I in retroviral budding.. J Virol 2003 Apr;77(8):4794-804.
              doi: 10.1128/jvi.77.8.4794-4804.2003pubmed: 12663786google scholar: lookup
            39. Ott DE, Coren LV, Sowder RC 2nd, Adams J, Schubert U. Retroviruses have differing requirements for proteasome function in the budding process.. J Virol 2003 Mar;77(6):3384-93.
              doi: 10.1128/jvi.77.6.3384-3393.2003pubmed: 12610113google scholar: lookup
            40. Freed EO. Viral late domains.. J Virol 2002 May;76(10):4679-87.
              doi: 10.1128/jvi.76.10.4679-4687.2002pubmed: 11967285google scholar: lookup
            41. Patnaik A, Chau V, Li F, Montelaro RC, Wills JW. Budding of equine infectious anemia virus is insensitive to proteasome inhibitors.. J Virol 2002 Mar;76(6):2641-7.
              doi: 10.1128/jvi.76.6.2641-2647.2002pubmed: 11861830google scholar: lookup
            Subscribe to our newsletter
            Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.